New treatments in spinal muscular atrophy: an overview of currently available data

References

• Sugarman EA, Nagan N, Zhu H, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimens. Eur J Hum Genet. 2012;20(1):27–32.
   PubMed Web of Science ®Google Scholar
• Munsat TL, Davies KE. International SMA Consortium Meeting (26-28 June 1992, Bonn, Germany). Neuromuscul Disord. 1992;2(5–6):423–428.
   PubMed Web of Science ®Google Scholar
• Dubowitz V. Ramblings in the history of spinal muscular atrophy. Neuromuscul Disord. 2009;19(1):69–73.
   PubMed Web of Science ®Google Scholar
• Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155–165.
   PubMed Web of Science ®Google Scholar
• Tiziano FD, Bertini E, Messina S, et al. The Hammersmith functional score correlates with the SMN2 copy number: A multicentric study. Neuromuscul Disord. 2007;17(5):400–403.
   PubMed Web of Science ®Google Scholar
• Prior TW, Krainer AR, Hua Y, et al. A positive modifier of spinal muscular atrophy in the SMN2 Gene. Am J Hum Genet. 2009;85(3):408–413.
   PubMed Web of Science ®Google Scholar
• Calucho M, Bernal S, Alías L, et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018;28(3):208–215.
   PubMed Web of Science ®Google Scholar
• Singh RN, Howell MD, Ottesen EW, et al. Diverse role of survival motor neuron protein. Biochim Biophys Acta. 2017;1860:299–315.
   PubMed Web of Science ®Google Scholar
• Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027–1049.
   PubMed Web of Science ®Google Scholar
• Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018; 28(2): 103–115.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3):197–207.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Mcdennott MP, Darras BT, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83:810–817.
   PubMed Web of Science ®Google Scholar
• Armstrong EP, Malone DC, Yeh WS, et al. The economic burden of spinal muscular atrophy. J Med Econ. 2016;19(8):822–826.
   PubMed Web of Science ®Google Scholar
• Klug C, Schreiber-Katz O, Thiele S, et al. Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2016;11(1):58.
   PubMedGoogle Scholar
• Chabanon A, Seferian AM, Daron A, et al. Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study. PLoS One. 2018 Jul 1;13(7):e0201004.
   PubMed Web of Science ®Google Scholar
• Foust KD, Braun L, Bevan AK, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol. 2010;28(3):271–274.
   PubMed Web of Science ®Google Scholar
• Hua Y, Vickers TA, Okunola HL, et al. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet. 2008;82(4):834–848.
   PubMed Web of Science ®Google Scholar
• Naryshkin NA, Weetall M, Dakka A, et al. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science. 2014;345(6197):688–693.
   PubMed Web of Science ®Google Scholar
• Kissel JT, Elsheikh B, King WM, et al. SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle Nerve. 2014;49(2):187–192.
   PubMed Web of Science ®Google Scholar
• Krosschell KJ, Kissel JT, Townsend EL, et al. Clinical trial of L-Carnitine and valproic acid in spinal muscular atrophy type I. Muscle Nerve. 2018 Feb 1;57(2):193–199.
   PubMed Web of Science ®Google Scholar
• Mercuri E, Bertini E, Messina S, et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord. 2004;14(2):130–135.
   PubMed Web of Science ®Google Scholar
• Chen TH, Chang JG, Yang YH, et al. Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy. Neurology. 2010;75(24):2190–2197.
   PubMed Web of Science ®Google Scholar
• Kinali M, Mercuri E, Main M, et al. Pilot trial of albuterol in spinal muscular atrophy. Neurology. 2002;59(4):609–610.
   PubMed Web of Science ®Google Scholar
• Mariot V, Joubert R, Hourdé C, et al. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat Commun. 2017;8(1):1859.
   PubMedGoogle Scholar
• Russman BS, Iannaccone ST, Samaha FJ, et al. 1 Trial of riluzole in spinal muscular atrophy. Arch Neurol. 2003;60(11):1601–1603.
   PubMed Web of Science ®Google Scholar
• Bertini E, Dessaud E, Mercuri E, et al. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(7):513–522.
   PubMed Web of Science ®Google Scholar
• Singh NN, Howell MD, Androphy EJ, et al. How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy. Gene Ther. 2017;24:520–526.
   PubMed Web of Science ®Google Scholar
• Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Invest Drugs.2012;4:562–573.
   Google Scholar
• Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMN Rx) in children with spinal muscular atrophy. Neurology. 2016;86(10):890–897.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017–3026.
   PubMed Web of Science ®Google Scholar
• Darras BT, Chiriboga CA, Iannaccone ST, et al. Nusinersen in later-onset spinal muscular atrophy. Neurology. 2019;92(21):2492–2506.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723–1732.
   PubMed Web of Science ®Google Scholar
• Aragon-Gawinska K, Daron A, Ulinici A, et al.; SMA-Registry Study Group. Sitting in nusinersen-treated spinal muscular atrophy type 1 patients. Dev Med Child Neurol. 2019 Dec 4. doi: 10.1111/dmcn.14412. [Epub ahead of print]
   Google Scholar
• Nusnersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019 Sep 12; pii: S0960-8966(19)31127-7. doi: 10.1016/j.nmd.2019.09.007. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625–635.
   PubMed Web of Science ®Google Scholar
• Farrar MA, Teoh HL, Carey KA, et al. Nusinersen for SMA: expanded access programme. J Neurol Neurosurg Psychiatry. 2018;89(9):937–942.
   PubMed Web of Science ®Google Scholar
• Pechmann A, Langer T, Schorling D. et al. Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany. Journal of Neuromuscular Disease. 2018;5(2):135–143.
   Google Scholar
• Messina S, Pane M, Sansone V, et al. Expanded access program with Nusinersen in SMA type I in Italy: strengths and pitfalls of a successful experience. Neuromuscul Disord. 2017;27(12):1084–1086.
   PubMed Web of Science ®Google Scholar
• Aragon-Gawinska K, Seferian AM, Daron A, et al. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: a cohort study. Neurology. 2018;91(14):1312–1318.
   PubMed Web of Science ®Google Scholar
• Gidaro T, Servais L. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. Dev Med Child Neurol. 2019;61(1):19–24.
   PubMed Web of Science ®Google Scholar
• Takanashi J Reader response: evidence in focus: Nusinersen use in spinal muscular atrophy 2018. [cited 2019 Dec 16]. https://n.neurology.org/content/reader-response-evidence-focus-nusinersen-use-spinal-muscular-atrophy.
   Google Scholar
• Weaver JJ, Natarajan N, Shaw DWW, et al. Transforaminal intrathecal delivery of nusinersen using cone-beam computed tomography for children with spinal muscular atrophy and extensive surgical instrumentation: early results of technical success and safety. Pediatr Radiol. 2018;48(3):392–397.
   PubMed Web of Science ®Google Scholar
• Young M, Fox MD, Puffenberger EG, et al. Preliminary safety and tolerability of a novel subcutaneous intrathecal catheter system for repeated outpatient dosing of nusinersen to children and adults with spinal muscular atrophy. J Pediatr Orthop. 2018;38(10):610–617.
   Web of Science ®Google Scholar
• Hamilton G, Gillingwater TH. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med. 2013;19:40–50.
   PubMed Web of Science ®Google Scholar
• Hua Y, Sahashi K, Rigo F, et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature. 2011;478(7367):123–126.
   PubMed Web of Science ®Google Scholar
• Foust KD, Nurre E, Montgomery CL, et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2009;27(1):59–65.
   PubMed Web of Science ®Google Scholar
• Valori CF, Ning K, Wyles M, et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med. 2010;2(35):35–42.
   Web of Science ®Google Scholar
• Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713–1722.
   PubMed Web of Science ®Google Scholar
• Al-Zaidy S, Pickard AS, Kotha K, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019;54(2):179–185.
   PubMed Web of Science ®Google Scholar
• Lowes LP, Alfano LN, Arnold WD, et al. Impact of age and motor function in a phase 1/2A study of infants with SMA Type 1 receiving single-dose gene replacement therapy. Pediatr Neurol. 2019;19:30280–30282.
   Google Scholar
• Mendell J, Lehman K, McColly M, et al. AVXS-101 Gene-Replacement Therapy (GRT) in Spinal Muscular Atrophy Type 1 (SMA1): long-term follow-up from the Phase 1 clinical trial (S25.006). Communication presented at American Academy of Neurology 2019-71st Annual Meeting; May 4-10, 2019, Philadelphia, PA, USA.
   Google Scholar
• Novartis announces AVXS-101 intrathecal study update. Novartis. [cited 2019 Dec 16]. https://www.novartis.com/news/media-releases/novartis-announces-avxs-101-intrathecal-study-update.
   Google Scholar
• Ratni H, Ebeling M, Baird J, et al. Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018;61(15):6501–6517.
   PubMed Web of Science ®Google Scholar
• Seabrook T, Baranello G, Servais L, et al. FIREFISH part 1: early clinical results following an increase of SMN protein in infants with type 1 spinal muscular atrophy (SMA) treated with risdiplam (RG7916). Communication presented at MDA Clinical & Scientific Conference; April 13-17, 2019; Orlando, Florida.
   Google Scholar
• Mercuri E, Baranello G, Kirschner J, et al. Update from SUNFISH Part 1: safety, tolerability and PK/PD from the dose-finding study, including exploratory efficacy data, in patients with type 2 or 3 spinal muscular atrophy (SMA) treated with risdiplam (RG7916). Communication presented at American Academy of Neurology 2019-71st Annual Meeting; May 4-10, 2019, Philadelphia, PA, USA.
   Google Scholar
• Roche’s risdiplam meets primary endpoint in pivotal SUNFISH trial in people with type 2 or 3 spinal muscular atrophy. Roche. [cited 2019 Dec 16]. https://www.roche.com/media/releases/med-cor-2019-11-11.htm.
   Google Scholar
• Palacino J, Swalley SE, Song C, et al. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat Chem Biol. 2015;11(7):511–517.
   PubMed Web of Science ®Google Scholar
• Son HW, Yokota T. Recent advances and clinical applications of exon inclusion for spinal muscular atrophy. Methods Mol Biol. 2018;1828:57–68.
   PubMedGoogle Scholar
• Jevtic S, Carr D, Dobrzycka-Ambrozevicz A, et al. Branaplam in Type 1 spinal muscular atrophy: second part of a phase I/II Study. Communication presented at 23rd SMA researcher meeting, Cure SMA; June 28-30, 2019; Anaheim, CA, USA.
   Google Scholar
• Dumonceaux J, Mariot V, Le Guiner C. et al. Myostatin expression is a reliable and quantifiable biomarker to monitor dose-dependent drug response in muscular dystrophy. Neuromuscul Disord. 2018;28(2):91.
   Google Scholar
• Rudnicki SA, Andrews JA, Malik FI, et al. CY 5021 A phase 2, double-blind, randomized, placebo-controlled, multiple-dose study of reldesemtiv 2 ascending-dose cohorts of patients with Spinal Muscular Atrophy (SMA). Communication presented at the Cure SMA 2018; June, 16, 2018; Dallas, TX, USA.
   Google Scholar
• Dangouloff T, Servais L. Clinical evidence supporting early treatment in spinal muscular atrophy: current perspectives. 2019;15:1153–1161. Therap Clin Risk Manage.
   PubMed Web of Science ®Google Scholar
• Chien YH, Chiang SC, Weng WC, et al. Presymptomatic diagnosis of spinal muscular atrophy through newborn screening. J Pediatr. 2017;190:124–129.
   PubMed Web of Science ®Google Scholar
• Kraszewski JN, Kay DM, Stevens CF, et al. Pilot study of population-based newborn screening for spinal muscular atrophy in New York state. Genet Med. 2018;20(6):608–613.
   PubMed Web of Science ®Google Scholar
• Boemer F, Caberg J-H, Dideberg V, et al. Newborn screening for SMA in southern Belgium. Neuromuscul Disord. 2019;29(5):343–349.
   PubMed Web of Science ®Google Scholar
• Boemer F, Caberg J, Dideberg V, et al. (S)un (M)ay (A)rise on SMA: l’espoir d’une région sans amyotrophie spinale [(S)un (M)ay (A)rise on SMA: hope for a region without spinal muscular atrophy]. Revue Medicale De Liege. 2019;74(9):461–464.
   PubMedGoogle Scholar
• Dangouloff T, Burghes A, Bertini E, et al. 244th ENMC International Workshop: Newborn screening in Spinal Muscular Atrophy, 10th-12th May 2019, Hoofdorp, The Netherlands. Neuromuscular disorders 2019; in press
   Google Scholar